Back to Stakeholders
Care Delivery & Psychedelic FacilitationPsychedelic Healthcare Implementation
Care Delivery & Psychedelic FacilitationPsychedelic Healthcare ImplementationPayer & Reimbursement Stakeholders

Aetna

U.S. private payer with published medical policy and prior-authorization requirements for esketamine (Spravato) in treatment-resistant depression pathways.

Reimbursement & Market Access Snapshot

Insurance Payers & Reimbursement Specialists

Service Model

Private / Commercial Payer

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 11, 2026

Focus Areas

Coverage Policy DesignFormulary & Access CriteriaPayment Coding Pathways

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessLong-Term Safety

Market Access Notes

Aetna maintains a dedicated clinical policy bulletin and a payer form specific to Spravato access decisions.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Primary Access Link

Linked Stakeholders

Institute for Clinical and Economic Review (ICER)

Source Evidence

Aetna Clinical Policy Bulletin 0950: Esketamine (Spravato)

https://www.aetna.com/cpb/medical/data/900_999/0950.html

Aetna Spravato Medication Precertification Request

https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/pharmacy-insurance/healthcare-professional/documents/spravato-medication-precert-form.pdf

Quick Facts

Website
Visit